ArticleMaterials today. Bio2026
Hepatic cavernous hemangioma decellularized extracellular matrix/GelMA composite hydrogel promotes angiogenesis via the ITGA9-FAK-ERK1/2 axis.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gelatin-Based Multifunctional Hydrogels for Sports Injury Repair: Musculoskeletal and Nervous System Perspectives.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective angiogenesis is crucial for tissue engineering and regenerative medicine. However, current strategies such as growth factor or endothelial cell (EC) delivery often face challenges in inducing stable and efficient vascularization. Inspired by mimicking matrix composition and physical architecture of vascular hyperplastic tissues, we developed a novel composite hydrogel composed of decellularized extracellular matrix from human hepatic cavernous hemangioma (HCH dECM) and gelatin methacryloyl (GelMA) to promote angiogenesis for tissue engineering applications. The HCH dECM/GelMA hydrogel exhibited improved mechanical stability, uniform porosity, and retention of pro-angiogenic basement membrane components, as confirmed by proteomic and biomechanical analyses. In vitro, the hydrogel significantly enhanced the viability, proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs), outperforming Matrigel in key morphological metrics. In a mouse subcutaneous implantation model, the HCH dECM/GelMA hydrogel robustly induced vascularization by recruiting host endothelial cells, as evidenced by increased CD31
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.